TrialDrug design, development and therapy2017

Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials.

Seokuee Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.